Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - cyproterone acetate ethinylestradiol - tablets - 2mg/35ug %v/v

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women -moderately severe to severe signs of androgenization -moderately severe/severe forms of hirsutism -moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenetic alopecia) -moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization,cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.,if cyprone 50 is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation.,men

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - cyproterone acetate ethinylestradiol - tablets - 2mg/35ug %v/v

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; pregelatinised maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. to suppress 'flare' with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - cyproterone acetate; ethinylestradiol - coated tablet - 2 mg/35 microgram(s) - cyproterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - cyproterone acetate; ethinylestradiol - coated tablet - 2 mg/35 microgram(s) - cyproterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - cyproterone acetate ; ethinylestradiol - coated tablets - 2/35 mg/mcg - cyproterone and estrogen - antiandrogens and estrogens - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, dianette should only be used after topical therapy or systemic antibiotic treatments have failed.

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - cyproterone acetate; ethinylestradiol ph.eur. - coated tablet - 2/35 milligram(s) - antiandrogens and estrogens; cyproterone and estrogen